{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05449444",
            "orgStudyIdInfo": {
                "id": "AB20006"
            },
            "secondaryIdInfos": [
                {
                    "id": "2021-005406-96",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "AB Science",
                "class": "INDUSTRY"
            },
            "briefTitle": "Masitinib for the Treatment of Severe Mast Cell Activation Syndrome",
            "officialTitle": "A 24-week, Multicenter, Randomized, Double Blind, Placebo-controlled, Dose-range Finding Phase II Study to Compare Efficacy and Safety of Oral Masitinib to Placebo in Treatment of Patients With Severe Mast Cell Activation Syndrome (MCAS) With Handicap Unresponsive to Optimal Symptomatic Treatment",
            "therapeuticArea": [
                "Rare Diseases"
            ],
            "study": "masitinib-for-the-treatment-of-severe-mast-cell-activation-syndrome"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-07-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-07-02",
            "studyFirstSubmitQcDate": "2022-07-06",
            "studyFirstPostDateStruct": {
                "date": "2022-07-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-02-03",
            "lastUpdatePostDateStruct": {
                "date": "2023-02-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AB Science",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.",
            "detailedDescription": "Multicenter, double-blind, placebo-controlled trial comparing two different dosing schemes over a 24-week treatment period.\n\nDosing scheme #1: Oral masitinib treatment at 3 mg/kg/day for 4 weeks, then a switch to 4.5 mg/kg/day for the remainder of the treatment period, versus placebo with a matching titration scheme. Randomization 2: 1 (Masitinib MCAS: Placebo MCAS).\n\nDosing scheme #2: Oral masitinib treatment at 3 mg/kg/day for 4 weeks, then a switch to 4.5 mg/kg/day for 4 weeks, then a second switch to 6 mg/kg/day for the remainder of the treatment period versus placebo treatment with a matching titration scheme. Randomization 2: 1 (Masitinib MCAS: Placebo MCAS)"
        },
        "conditionsModule": {
            "conditions": [
                "Mast Cell Activation Syndrome"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Randomized, double-blind, placebo-controlled, parallel-group, multicenter comparative study with ascending dose titrations of masitinib and matching placebo",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "Eligible patients will be randomized by means of a computerized central randomization system called IWRS (interactive web response system).",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 72,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Masitinib (4.5) & BSC",
                    "type": "EXPERIMENTAL",
                    "description": "Masitinib 4.5 mg/kg/day administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC). Participants receive masitinib (3.0 mg/kg/day) for 4 weeks, given orally twice daily, with a dose escalation to 4.5 mg/kg/day for the remainder of the treatment period. Each ascending dose titration is subjected to a safety control.",
                    "interventionNames": [
                        "Drug: Masitinib 4.5 mg/kg/day",
                        "Other: Best supportive care"
                    ]
                },
                {
                    "label": "Masitinib (6.0) & BSC",
                    "type": "EXPERIMENTAL",
                    "description": "Masitinib 6.0 mg/kg/day administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC). Participants receive masitinib (3.0 mg/kg/day) for 4 weeks, given orally twice daily, with a dose escalation to 4.5 mg/kg/day for4 weeks of treatment, then a second dose escalation to 6 mg/kg/day for the remainder of the treatment period. Each ascending dose titration is subjected to a safety control.",
                    "interventionNames": [
                        "Other: Best supportive care",
                        "Drug: Masitinib 6.0 mg/kg/day"
                    ]
                },
                {
                    "label": "Placebo & BSC",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC). Participants receive a matched dose placebo, given orally twice daily.",
                    "interventionNames": [
                        "Drug: Placebo",
                        "Other: Best supportive care"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Masitinib 4.5 mg/kg/day",
                    "description": "Masitinib 4.5 mg/kg/day",
                    "armGroupLabels": [
                        "Masitinib (4.5) & BSC"
                    ],
                    "otherNames": [
                        "AB1010"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Matching placebo",
                    "armGroupLabels": [
                        "Placebo & BSC"
                    ],
                    "otherNames": [
                        "Placebo Oral Tablet"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Best supportive care",
                    "description": "Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.",
                    "armGroupLabels": [
                        "Masitinib (4.5) & BSC",
                        "Masitinib (6.0) & BSC",
                        "Placebo & BSC"
                    ],
                    "otherNames": [
                        "BSC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Masitinib 6.0 mg/kg/day",
                    "description": "Masitinib 6.0 mg/kg/day",
                    "armGroupLabels": [
                        "Masitinib (6.0) & BSC"
                    ],
                    "otherNames": [
                        "AB1010"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Confirmed response at 50%",
                    "description": "Confirmed response at 50%, defined as an improvement with respect to the baseline values of 50% for Pruritus, Flushes and Depression (HAMD-17 score) which should be confirmed from the previous visit.\n\nHandicaps at baseline defined as: pruritus score \u2265 9; number of flushes per week \u2265 8; HAMD-17 score \u2265 19.",
                    "timeFrame": "24 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Cumulative response",
                    "description": "Cumulative (every patient visit) response at 75% on 3 handicaps (pruritus, flush, depression) from week 8 to week 24. Analysis will be performed using Generalized Estimating Equations (GEE) model with stratification.",
                    "timeFrame": "week 8 to week 24"
                },
                {
                    "measure": "Confirmed response (75%)",
                    "description": "Confirmed response at 75%, defined as an an improvement with respect to the baseline values of 75% for Pruritus, Flushes and Depression (Hamilton Depression Rating Scale) which should be confirmed from the previous visit. The Hamilton Depression Rating Scale (HAMD-17) has 17 items and is scored between 0 and 4 points. Scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression; the maximum score being 52.",
                    "timeFrame": "24 weeks"
                },
                {
                    "measure": "Patient-Reported Outcome for Symptom Severity (PROSS)",
                    "description": "Changes in MCAS symptom severity will also be assessed using the Patient-Reported Outcome for Symptom Severity (PROSS) questionnaire. Total and individual symptom scores will be determined at baseline and at every visit until Week 24.The PROSS questionnaire has 11 items and is scored between 0 and 10 points. A score of 0 is an absence of the symptom and a score of 10 is very severe; the maximum score being 110.",
                    "timeFrame": "24 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria include:\n\n* Patient with mast cell activation syndrome (MCAS).\n* Patient with severe symptoms over the 14-day run-in period defined as at least one of the following: Pruritus score \u2265 9; Number of flushes per week \u2265 8; Hamilton rating scale for depression (HAMD-17) score \u2265 19\n* Patient with documented treatment failures of his/her handicap(s) (within last two years) with at least two of the symptomatic treatments used at optimized dose.\n* Patients must be on a stable dose of Anti-H1 for a minimum of 4 weeks before screening and should remain at a stable dose throughout the study period.\n\nExclusion Criteria include:\n\n* Previous treatment with any Tyrosine Kinase Inhibitor.\n* Any change in the symptomatic treatment of MCAS, including systemic corticosteroids, or administration of any new treatment for MCAS within 4 weeks prior to screening.\n* Patient with systemic indolent mastocytosis.\n* Female patients who are pregnant or are breastfeeding.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Study Coordinator",
                    "role": "CONTACT",
                    "phone": "+33(0)147200014",
                    "email": "clinical@ab-science.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Julien Rossignol, MD",
                    "affiliation": "Reference Centre for Mastocytosis (CEREMAST), Necker Hospital, Paris, France",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "St Charles Clinical Research",
                    "status": "RECRUITING",
                    "city": "Weldon Spring",
                    "state": "Missouri",
                    "zip": "63304",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.71339,
                        "lon": -90.68929
                    }
                },
                {
                    "facility": "Centre Hospitalier Universitaire Amiens-Picardie",
                    "status": "RECRUITING",
                    "city": "Amiens",
                    "country": "France",
                    "geoPoint": {
                        "lat": 49.9,
                        "lon": 2.3
                    }
                },
                {
                    "facility": "Necker-Enfants Malades Hospital, Centre de r\u00e9f\u00e9rence des Mastocytoses (CEREMAST)",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "CHU Toulouse",
                    "status": "RECRUITING",
                    "city": "Toulouse",
                    "country": "France",
                    "geoPoint": {
                        "lat": 43.60426,
                        "lon": 1.44367
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "28069279",
                    "type": "BACKGROUND",
                    "citation": "Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017 Feb 11;389(10069):612-620. doi: 10.1016/S0140-6736(16)31403-9. Epub 2017 Jan 7."
                },
                {
                    "pmid": "36048877",
                    "type": "DERIVED",
                    "citation": "Latham BD, Oskin DS, Crouch RD, Vergne MJ, Jackson KD. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chem Res Toxicol. 2022 Sep 19;35(9):1467-1481. doi: 10.1021/acs.chemrestox.2c00057. Epub 2022 Sep 1."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "No Masitinib is under clinical investigation and has not yet been approved in any sought-after indication by any health authority worldwide. As such, there is no plan for data-sharing at this point in time."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000090267",
                    "term": "Mast Cell Activation Syndrome"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000090362",
                    "term": "Mast Cell Activation Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2769",
                    "name": "Mast Cell Activation Syndrome",
                    "asFound": "Mast Cell Activation Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2776",
                    "name": "Mast Cell Activation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3624",
                    "name": "Mast Cell Activation Syndrome",
                    "asFound": "Mast Cell Activation Syndrome",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M9709",
                    "name": "Histamine Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M9710",
                    "name": "Histamine H1 Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M4247",
                    "name": "Antidepressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M21876",
                    "name": "Leukotriene Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M27630",
                    "name": "Proton Pump Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7386",
                    "name": "Cromolyn Sodium",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "AAll",
                    "name": "Anti-Allergic Agents"
                },
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                }
            ]
        }
    },
    "hasResults": false
}